Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Novavax, Inc.    

NOVAVAX, INC.

 SummaryChartsNewsRatingsCompany 
Company
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline... 
More about the company
Surperformance© ratings of Novavax, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVAVAX, INC.
2019Novavax Reports Fourth Quarter and Year-End 2018 Financial Results
GL
2019Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 F..
GL
2019Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVax&trad..
GL
2018Novavax Expands Leadership with Several Key Management Promotions
GL
2018NOVAVAX : New England Journal of Medicine Publishes Novavax' NanoFlu Clinical Tr..
GL
2018NOVAVAX : CEO to Discuss Future of Global Vaccine Business as Part of Panel of I..
PU
2018NOVAVAX : Reports First Quarter 2018 Financial Results
GL
2018NOVAVAX : Reaches Significant Enrollment Milestone in the Prepare(TM) Phase 3 Tr..
GL
2018NOVAVAX : to Host Conference Call to Discuss First Quarter Financial Results on ..
GL
2018NOVAVAX : Announces Closing of Public Offering
GL
2018NOVAVAX : Prices Public Offering of Common Stock
GL
2018Novavax Prices Public Offering of Common Stock
GL
2018Novavax Announces Proposed Public Offering of Common Stock
GL
2018Novavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at Worl..
GL
2018NOVAVAX : to Present Clinical Data on RSV F and NanoFlu(TM) Vaccines at World Va..
GL
More news
News in other languages on NOVAVAX, INC.
2019Novavax Reports Fourth Quarter and Year-End 2018 Financial Results
2019Novavax to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 F..
2019Novavax Announces Topline Results from Phase 3 PrepareTM Trial of ResVax&trad..
2018Novavax Expands Leadership with Several Key Management Promotions
2018WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Stanley C. Erck President, Chief Executive Officer & Director
James F. Young Chairman
John J. Trizzino CFO, Treasurer, Chief Business Officer & Senior VP
Gregory M. Glenn President-Research & Development
Louis F. Fries Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVAVAX, INC.213.04%2 370
LONZA GROUP33.49%36 433
IQVIA HOLDINGS INC.-3.23%28 553
SEATTLE GENETICS, INC.37.59%27 213
MODERNA, INC.214.42%23 913
CELLTRION, INC.17.96%23 085